Is Estrella Immunopharma, Inc. (ESLA) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 9.3% / 30% | 0.6% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 9.3% / 33% | 0.6% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 93.5% / 33% | 6.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 9.3% / 33% | 0.6% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 93.5% / 33% | 6.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -258.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$16M |
| Free Cash Flow | -$16M |
| Current Ratio | 0.1 |
| Total Assets | $4M |
Price & Trading
| Last Close | $1.04 |
| 50-Day MA | $1.14 |
| 200-Day MA | $1.31 |
| Avg Volume | 177K |
| Beta | 0.5 |
|
52-Week Range
$0.73
| |
About Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Estrella Immunopharma, Inc. (ESLA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Estrella Immunopharma, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Estrella Immunopharma, Inc.'s debt ratio?
Estrella Immunopharma, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Estrella Immunopharma, Inc.'s key financial metrics?
Estrella Immunopharma, Inc. has a market capitalization of $45M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.